Claims for Patent: 10,786,577

Summary for Patent: 10,786,577

Title:	Pharmaceutical composition comprising glutatione disulfide and glutathione disulfide S-oxide
Abstract:	Pharmaceutical composition comprising glutathione disulphide or pharmaceutically acceptable organic or inorganic salt thereof and glutathione disulfide S-oxide of the following structure: ##STR00001## or pharmaceutically acceptable organic or inorganic salt thereof for eliminating dose-related toxicity and enhancing the therapeutic activity of a pharmacologically active compound in the treatment of infectious and non-infectious diseases is provided. Typically, the composition comprises glutathione disulfide S-oxide in an amount of 0.01-10% by weight of the total composition, and additionally a metal (Me) in the form of coordination compound(s) containing Me-S-glutathione bond, said metal is selected from the platinum group, typically it is platinum. The amount of d-metal coordination compound administered to a patient can be 10.sup.-3 to 10.sup.-15 mol/kg of body weight. The composition can be used in combination with pharmacologically active compound, which is an anticoagulant, factor Xa inhibitor, antimicrobial or antiviral agents to increase their therapeutic activity and eliminate dose-related toxicity.
Inventor(s):	Balazovskij; Mark Borisovich (St. Petersburg, RU), Antonov; Viktor Georgievich (St. Petersburg, RU), Ignatenko; Oleg Aleksandrovich (St. Petersburg, RU)
Assignee:	OBSCHESTVO S ORGANICHENNOY OTVETSTVENNOSTJU \"IVA FARM\" (St. Petersburg, RU)
Application Number:	16/603,042
Patent Claims:	1. A pharmaceutical composition for treating dose-related toxicity and enhancing the therapeutic activity of a pharmacologically active compound in the treatment of infectious and non-infectious diseases, comprising glutathione disulfide or pharmaceutically acceptable organic or inorganic salt thereof and glutathione disulfide S-oxide of the following structure: ##STR00003## or pharmaceutically acceptable organic or inorganic salt thereof, wherein said composition further comprises a d-metal (Me) selected from the platinum group, and wherein the amount of d-metal in the composition ranges from 1.times.10.sup.-10 moles to 1.times.10.sup.-3 moles per 1 kg of the composition. 2. The pharmaceutical composition of claim 1, wherein the amount of glutathione disulfide S-oxide is 0.01-10% by weight of the total composition. 3. The pharmaceutical composition of claim 1, wherein the metal is platinum. 4. The pharmaceutical composition of claim 1, wherein the amount of d-metal in the composition is 1.times.10.sup.-5 moles per 1 kg of the composition. 5. A pharmacological combination for treating dose-dependent toxicity and enhancing the therapeutic activity of a pharmacologically active compound in the treatment of infectious and non-infectious diseases, comprising the composition of claim 1 and pharmacologically active compound selected from the group of anticoagulant, factor Xa inhibitor, antimicrobial or antiviral agent, calcium channel inhibitor. 6. The pharmacological combination of claim 5, wherein non-infectious disease is thromboses, where the pharmacologically active compound is anticoagulant, factor Xa inhibitor amidine hydrochloride. 7. The pharmacological combination of claim 5, wherein said infectious disease is caused by Gram-negative and Gram-positive bacteria, selected from the group consisting of Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, Listeria monocytogenes EGD, Staphylococcus aureus, MRSA--methicillin-resistant Staphylococcus aureus, and wherein the pharmacologically active compound is antimicrobial agent moxifloxacin. 8. The pharmacological combination of claim 5, wherein the infectious disease is a viral disease, where the pharmacologically active compound is antiviral agent. 9. The pharmacological combination of claim 8, wherein the viral disease is rabies, wherein the pharmacologically active compound is antigenic material of anti-rabies vaccine. 10. A medicament for treating dose-related toxicity and enhancing the therapeutic activity of a pharmacologically active compound in the treatment of infectious and non-infectious diseases, comprising at least one pharmaceutical composition according to claim 1 in a therapeutically effective amount together with pharmaceutically acceptable excipients. 11. A medicament for treating dose-related toxicity and enhancing the therapeutic activity of a pharmacologically active compound in the treatment of infectious and non-infectious diseases, comprising at least one pharmacological combination according to claim 5 in a therapeutically effective amount together with pharmaceutically acceptable excipients. 12. The medicament for treating dose-related toxicity and enhancing the therapeutic activity of a pharmacologically active compound in the treatment of infectious and non-infectious diseases, according to claim 10, wherein said medicament can be manufactured for external, inhalational, enteral or parenteral administration. 13. A method of treating a second phase of xenobiotic detoxification by administering the pharmaceutical composition of claim 1. 14. A method of treating a viral diseases associated with interferon alpha activity by administering the pharmaceutical composition of claim 1.

Details for Patent 10,786,577

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bavarian Nordic A/s	RABAVERT	rabies vaccine	For Injection	103334	October 20, 1997	10,786,577	2037-11-17
Sanofi Pasteur Sa	IMOVAX RABIES	rabies vaccine	For Injection	103931	February 04, 2000	10,786,577	2037-11-17